There is, therefore, a role for BCMA x CD3 BiTEs in the setting of BCMA CAR‐T relapse; however, it is not clear how this approach would compare with targeting a different MM antigen with CAR‐T, BiTE or other therapy. Here, TNFRSF17 is linked to Miyoshi myopathy.